Buspirone Should Be Discontinued at Least 48 Hours Before PSG/MSLT Testing
Buspirone must be stopped prior to polysomnography and MSLT testing in patients being evaluated for narcolepsy because it can cause false-positive results on laboratory assays and may alter sleep architecture, potentially confounding the diagnostic evaluation. 1
Critical Drug-Test Interference
The FDA label explicitly warns that buspirone hydrochloride interferes with urinary metanephrine/catecholamine assays and has been mistakenly identified as metanephrine during routine testing, resulting in false-positive laboratory results. 1 While this specific warning relates to pheochromocytoma testing, it demonstrates buspirone's capacity to interfere with diagnostic procedures.
The FDA recommends discontinuing buspirone for at least 48 hours prior to undergoing urine collection for catecholamines. 1 This same precautionary principle should be applied to sleep testing, given the drug's effects on sleep architecture.
Effects on Sleep Architecture
Buspirone has documented effects on sleep that would directly compromise MSLT and PSG interpretation:
- Increases sleep latency (the time it takes to fall asleep)
- Decreases total sleep time through reductions in both non-REM and REM sleep
- Acts as a respiratory stimulant with effects persisting during sleep
- These effects are independent of wakefulness and persist during non-REM sleep 2
These pharmacologic properties would artificially prolong sleep latency on MSLT testing, potentially masking narcolepsy. A patient with true narcolepsy (characterized by mean sleep latency ≤8 minutes and ≥2 sleep-onset REM periods) could have falsely normal results if buspirone extends their sleep latency beyond diagnostic thresholds.
Mechanism and Duration of Action
Buspirone has:
- Moderate affinity for brain D2-dopamine receptors
- No significant affinity for benzodiazepine receptors
- Elimination half-life of 2-3 hours after single doses 1
- Nonlinear pharmacokinetics with repeated dosing potentially leading to higher blood levels than predicted 1
Given the 2-3 hour half-life, a 48-hour washout period (approximately 16-24 half-lives) ensures complete drug elimination and resolution of pharmacodynamic effects on sleep architecture.
Clinical Recommendation Algorithm
For patients on buspirone being evaluated for narcolepsy:
- Discontinue buspirone at least 48 hours before PSG (the night before MSLT)
- Maintain discontinuation through MSLT completion (typically performed the day after PSG)
- Document the washout period in the sleep study report
- Consider alternative anxiolytic management during the brief washout if clinically necessary (coordinate with prescribing physician)
Important Caveats
- Hepatic impairment: Patients with liver disease show 13-fold increases in buspirone AUC at steady state, potentially requiring longer washout periods 1
- Renal impairment: Patients with kidney disease show 4-fold increases in AUC, also potentially requiring extended washout 1
- Drug interactions: Patients taking CYP3A4 inhibitors (ketoconazole, ritonavir, erythromycin, grapefruit juice) may have significantly elevated buspirone levels requiring longer washout periods 1
The standard 48-hour washout may be insufficient in patients with hepatic/renal impairment or those on CYP3A4 inhibitors—consider 72-96 hours in these populations.
Context Within Narcolepsy Evaluation
This recommendation aligns with standard practice for narcolepsy evaluation, where any medication affecting sleep architecture or REM sleep should be discontinued before diagnostic testing. The 2021 AASM guidelines for narcolepsy treatment 3 do not list buspirone as a recommended treatment for narcolepsy, making its discontinuation for diagnostic purposes straightforward without compromising disease-specific therapy.